|
WO2020230802A1
|
|
Method for producing 4-oxopyrrolidine-3-carboxamide derivatives
|
|
WO2020160151A1
|
|
15-pgdh inhibitors
|
|
WO2020080505A1
|
|
Effervescent tablet containing sodium dichloroisocyanurate
|
|
WO2020040104A1
|
|
Bicyclic heteroaromatic ring derivative
|
|
WO2020022507A1
|
|
Agent for inhibiting recurrence of hematological malignancy in patients who have undergone hematopoietic stem cell transplantation
|
|
JP2021001122A
|
|
Pharmaceutical solid preparation with masked agent having discomfort functional properties
|
|
JP2019104761A
|
|
Method for producing tablet containing imidafenacin by direct tableting
|
|
WO2020152869A1
|
|
Therapeutic agent for fibrosis
|
|
CN111556753A
|
|
Therapeutic agent for nocturnal pollakisuria
|
|
JP2019019148A
|
|
Method for producing formulation containing imidafenacin with excellent storage stability
|
|
JP2018203789A
|
|
Granulated material containing imidafenacin having less production process decomposed product
|
|
US2021087556A1
|
|
Therapeutic agent for fibrosis
|
|
CA3067188A1
|
|
Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess
|
|
WO2018230686A1
|
|
Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess
|
|
JP2018168108A
|
|
Method for producing formulation containing imidafenacin by extrusion granulating
|
|
JP2018168106A
|
|
Method for producing tablet containing imidafenacin by direct tableting
|
|
JP2018168111A
|
|
Method for producing granulated material containing imidafenacin by wet granulation method
|
|
JP2018168112A
|
|
Imidafenacin-containing tablet
|
|
JP2018168113A
|
|
Coating granule of imidafenacin-containing granulated material
|
|
JP2018168109A
|
|
Method for producing formulation containing imidafenacin by agitation granulating
|
